Skip to main content

Neumora Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

NMRA$0.49-3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Neumora Therapeutics, Inc.
Date: March 7, 2024By:/s/ Henry O. Gosebruch
Name:Henry O. Gosebruch
Title:Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Henry O. Gosebruch and Joshua Pinto, Ph.D, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

NameTitleDate
/s/ Henry O. GosebruchChief Executive OfficerMarch 7, 2024
Henry O. Gosebruch(principal executive officer)
/s/ Joshua Pinto, Ph.DChief Financial OfficerMarch 7, 2024
Joshua Pinto, Ph.D(principal financial officer)
/s/ Michael MilliganPrincipal Accounting OfficerMarch 7, 2024
Michael Milligan
/s/ Paul L. BernsDirectorMarch 7, 2024
Paul L. Berns
/s/ Kristina BurowDirectorMarch 7, 2024
Kristina Burow
/s/ Matthew K. FustDirectorMarch 7, 2024
Matthew K. Fust
/s/ Alaa HalawaDirectorMarch 7, 2024
Alaa Halawa
/s/ Maykin Ho, Ph.DDirectorMarch 7, 2024
Maykin Ho, Ph.D
/s/ David PiacquadDirectorMarch 7, 2024
David Piacquad
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.